Login to Your Account



Vascular-Targeting Agent Fights AML

By Anette Breindl
Science Editor

Thursday, September 5, 2013
Mention “vasculature” and “cancer drug” in the same sentence, and most people with think anti-angiogenesis. Which, with blockbusters like Avastin (bevacizumab, Roche AG) on the market and dozens of angiogenesis inhibitors in development, is not surprising. Angiogenesis aims to block the formation of new blood vessels, cutting off tumors’ supply of oxygen and nutrients. But blood vessels can be used therapeutically in cancers without trying to destroy them: through an approach known as vascular targeting.

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription